Clinical manifestations, genetic profiles, and sudden cardiac arrest in pediatric hypertrophic cardiomyopathy: Challenges of risk prediction for initial sudden cardiac arrest presentations.

BACKGROUND

Sudden cardiac arrest (SCA) is a leading cause of death in pediatric hypertrophic cardiomyopathy (HCM).

OBJECTIVE

The study sought to analyze the clinical and genetic characteristics of pediatric HCM and assess the applicability of current SCA risk prediction models.

METHODS

We enrolled individuals diagnosed as HCM before 20 years of age, between 2000 and 2020, excluding those secondary to hemodynamic causes and those associated with genetic syndromes other than RASopathies.

RESULTS

Among 91 patients (31 female, 60 male), SCA occurred in 13 (14.3%) patients, with 6 (46%) cases presenting as the initial symptom. These 6 patients were older and had lower left ventricular mass scores compared with those who experienced SCA later during follow-up. Whole exome sequencing in 55 patients identified genetic pathogenic variants in 80% of cases. The most prevalent pathogenic variants were MYH7 (40%) and MYBPC3 (24%) within the sarcomere gene group, and RAF1 (36.8%) and PTPN11 (21.1%) among RASopathies. SCA events occurred mostly between 10 and 18 years of age. The SCA event-free survival rate was 84.2% by 10 years after diagnosis and associated with sarcomere gene pathogenic variants (odds ratio 10.2). Excluding the 6 patients presented as SCA initially, both the HCM Risk-Kids and PRIMaCY (precision medicine in cardiomyopathy) genetic scoring system exhibited strong predictive power for SCA during follow-up.

CONCLUSION

In pediatric HCM, SCA is notably associated with sarcomere gene pathogenic variants. While newer risk scoring systems, if incorporated with genetic information, effectively predict SCA in this Asia cohort, a challenge remains: nearly half of SCA cases present as the initial clinical manifestation.